Personalized Cancer Therapy for Urological Cancers: From Bench to Bedside and Back
1Department of Urology, Kinki University School of Medicine, Osakasayama, Osaka, 589-8511 Japan
2Prostate Cancer Research, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland 4101, Australia
3Department of Experimental Urology, University Medical Center, 6525 Nijmegen, The Netherlands
4Department of Surgery, University of Toronto, Division of Urology, Sunnybrook Health Sciences Center, Toronto, ON, Canada M4N 3M5
Personalized Cancer Therapy for Urological Cancers: From Bench to Bedside and Back
Description
Recent advances in the fields of genomics, proteomics, pharmacogenomics, and immunology have ushered in a new era in personalized medicine promising more effective and well-tolerated treatments for cancer patients. With continued progress, patients suffering from urological cancer would be excellent candidates to receive benefits from such treatments making personalized therapy a reality.
Although modest achievements have been produced, much is yet to be actualized in order to consider personalized medicine in urological malignancies a success. However, the complexity of the disease process, limited availability of predictive and prognostic biomarkers, and variability in individual responses and eventual relapses add to the challenges that clinicians and researchers must tackle in order to make the dream a reality.
Therefore, it is eminent for the success of personalized medicine to rely on a cross-disciplinary approach that requires the integration between different scientific disciplines and interactions between the research scientists, biostatisticians, and physicians. Using this “systems biology” approach, a new perspective is achieved that may better help us address basic and translational advances that will then be tested and assessed clinically generating feedback to the research scientist.
With this theme in mind, we invite authors to submit original and review articles that will focus on the current state and major advances towards the concept of personalized cancer medicine for urological cancers with an emphasis on prediction, treatment, and prevention. Potential topics include, but are not limited to:
- Molecularly targeted therapy
- Vaccine therapy
- Gene therapy
- New and emerging technologies
- Biomarkers (predictive, prognostic, and diagnostic)
- Proteomics
- Genomics
- Pharmacogenomics
- Targeted chemoprevention
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/au/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: